Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:58:24 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Optomed Q2 2023 - Waiting game

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Optomed Q2 2023 - Waiting game

2023-08-07 08:25:00

Redeye provides an update in relation to Optomed’s Q2 2023 report. The report aligned with our expectations and did not include any major surprises. However, we note that the additional data has not been sent in yet to the FDA. We now expect a potential FDA approval during Q4 2023 and only make some minor estimate changes for Q3-Q4 2023e. Moreover, we believe an exciting half-year is ahead of Optomed and argue the share is currently traded at low levels, significantly lower than our reiterated base case of EUR8.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/